Artiva Biotherapeutics, Inc.
Data quality: 100%
ARTV
Nasdaq
Manufacturing
Chemicals
$6.68
▲
$0.49
(7.92%)
Mkt Cap: 165.11 M
Price
$6.68
Mkt Cap
165.11 M
Day Range
$6.13 — $7.15
52-Week Range
$1.47 — $7.75
Volume
177,001
Open $6.13
50D / 200D Avg
$5.16
29.36% above
50D / 200D Avg
$3.74
78.59% above
Quick Summary
Key Takeaways
Negative free cash flow of -79.34 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)-100.00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-60.28%
Below sector avg (-53.41%)
ROIC-47.88%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio11.65
Interest CoverageN/A
Valuation
PE (TTM)
-1.97
Below sector avg (-1.48)
P/B Ratio1.28
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -2.0 | -1.5 |
| P/B | 1.3 | 1.6 |
| ROE % | -60.3 | -53.4 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -100.00% | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0.0 | Net Income (TTM) | -83.87 M |
| ROE | -60.28% | ROA | -52.70% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -79.34 M |
| ROIC | -47.88% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 11.65 |
| Interest Coverage | N/A | Asset Turnover | 0.00 |
| Working Capital | 118.41 M | Tangible Book Value | 129.22 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1.97 | Forward P/E | N/A |
| P/B Ratio | 1.28 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -48.05% | ||
| Market Cap | 165.11 M | Enterprise Value | 139.60 M |
| Per Share | |||
| EPS (Diluted TTM) | -3.43 | Revenue / Share | 0.00 |
| FCF / Share | -3.21 | OCF / Share | -3.11 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 94.60% |
| SBC-Adj. FCF | -87.46 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | 0.0 | 251,000.0 |
| Net Income | -83.87 M | -65.37 M |
| EPS (Diluted) | -3.43 | -5.81 |
| Gross Profit | — | — |
| Operating Income | -89.81 M | -67.28 M |
| EBITDA | — | — |
| R&D Expenses | 69.54 M | 50.33 M |
| SG&A Expenses | — | — |
| D&A | 2.60 M | 2.43 M |
| Interest Expense | — | — |
| Income Tax | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 |
|---|---|---|
| Total Assets | 130.94 M | 209.58 M |
| Total Liabilities | 20.97 M | 22.94 M |
| Shareholders' Equity | 109.97 M | 186.64 M |
| Total Debt | — | — |
| Cash & Equivalents | 26.70 M | 40.24 M |
| Current Assets | 112.67 M | 188.63 M |
| Current Liabilities | 13.09 M | 12.25 M |
{"event":"ticker_viewed","properties":{"ticker":"ARTV","listing_kind":"stock","pathname":"/stocks/artv","exchange":"Nasdaq","country":"US"}}